engleski

Sertraline and 5-HT markers in platelets of depressed patients

Serotonin (5-HT) may be involved in the pathophysiology of depressive disorders. The role of 5-HT in the etiology and treatment of depression was investigated using blood platelets as a peripheral model for central presynaptic serotonergic synaptosomes. The present study examines platelet 5-HT concentration, 3H-paroxetine binding and platelet monoamine oxidase (MAO) activity in 21 nonpsychotic, nonsuicidal depressed female patients (DSM-IV criteria), before (baseline, i.e. after 8 days of wash-out period) and during (4 and 24 weeks) treatment with sertraline ( a selective serotonergic reuptake inhibitor, SSRI). When compared to baseline levels, repeated administration of sertraline (25-100 mg daily) markedly decreased platelet 5-HT levels, and did not change 3H-paroxetine binding and platelet MAO activity. From 15 nonpsychotic depressed patients who finished 24-weeks treatment with sertraline, complete clinical improvement ( based on the reductions in HAMD and MADRS scores) was seen in 11 patients, whereas 4 patients showed partial clinical improvement. These results confirmed that alterations in 5-HT system are included in antidepressant action of sertraline.

platelet serotonin; platelet MAO; 3H-paroxetine binding; depressive disorders; sertraline

nije evidentirano